secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950142-23-000074
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q4 core revenue $26-27M, seq growth 4-9%; restructuring on track
--------------------------------------------------------------------------------

- Preliminary Q4 core revenue $26-27M (4-9% sequential growth); FY 2022 ~$94-95M.
- Restructuring reduces opex >$30M (20%+); headcount cut 15%, real estate 25%.
- Targets positive free cash flow by Q4 2024; year-end cash $165M.
- Non-GAAP gross margin goal 65-68% by end of 2023; GAAP 52-55%.
- Appointed Betsy Jensen CHRO; Hyperion XTi imaging system on track with 2 early units shipped.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/eh230318897_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer